Taro Pharmaceutical Industries Ltd.
TARO · NYSE
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $1,587,210 | $1,570,297 | $1,417,326 | $1,425,595 |
| - Cash | $362,909 | $382,409 | $269,011 | $124,165 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1,224,301 | $1,187,888 | $1,148,315 | $1,301,430 |
| Revenue | $164,941 | $157,145 | $148,202 | $158,894 |
| % Growth | 5% | 6% | -6.7% | – |
| Gross Profit | $87,389 | $79,881 | $73,602 | $64,084 |
| % Margin | 53% | 50.8% | 49.7% | 40.3% |
| EBITDA | $18,062 | $23,119 | $13,969 | $6,170 |
| % Margin | 11% | 14.7% | 9.4% | 3.9% |
| Net Income | $15,078 | $20,208 | $8,547 | $10,033 |
| % Margin | 9.1% | 12.9% | 5.8% | 6.3% |
| EPS Diluted | 0.4 | 0.54 | 0.23 | 0.27 |
| % Growth | -25.9% | 134.8% | -14.8% | – |
| Operating Cash Flow | $44,241 | $30,925 | $47,516 | $7,777 |
| Capital Expenditures | -$7,945 | -$34,478 | -$7,006 | -$6,844 |
| Free Cash Flow | $36,296 | -$3,553 | $40,510 | $933 |